Knowledge graph · Cancer
Anaplastic Large Cell Lymphoma
hematologic malignancy
- Identifier
- CI-CAN-00000444
- Entity page
- /cancer/anaplastic-large-cell-lymphoma ↗
- Edges
- 314
- Neighbours
- 1 genes2 variants22 drugs10 trials
- Drawn
- 35 of 35 neighbours (cap 60); table lists every fetched edge
Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.
Most connectedLung Non-Small Cell Carcinoma 3,149Malignant Colorectal Neoplasm 1,866ABL1 298EGFR 276Imatinib 450Dasatinib 321
Neighbourhood
Radial view
Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.
Edges
Every edge, grouped by relationship
Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.
| Relationship | Neighbour | Direction | Evidence level | Cancer context | Support | Claim | Source | Expand |
|---|---|---|---|---|---|---|---|---|
| Anaplastic Large Cell Lymphoma approved for …APPROVED_FOR2 of 1 | ||||||||
| ← approved for | Crizotinibsmall_molecule 2 source records aggregated | supports | FDA ORIG | Anaplastic Large Cell Lymphoma | 2 | Regulatory | openfda | graph → |
| ← approved for | Brentuximab Vedotinadc FDA (US) · approved · 2011-08-19 · . • Adult patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen | |||||||